StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) Reports Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results at ESC Congress 2018
August 27, 2018 5:40 AM
Pfizer Inc. (NYSE: PFE) announced today the primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, which showed ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Pfizer (PFE) PT Raised to $45 at Goldman Sachs
August 28, 2018 7:48 AM
Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018
August 27, 2018 5:21 AM
Pfizer (PFE) PT Raised to $45 at Morgan Stanley
August 23, 2018 6:52 AM
Pfizer (PFE) PT Raised to $40 at Barclays
August 23, 2018 4:44 AM